Shin S U
UCLA, Department of Microbiology 90024.
Biotherapy. 1991;3(1):43-53. doi: 10.1007/BF02175098.
Antibodies, because of their inherent specificity, seem ideal agents for recognizing and destroying malignant cells. When monoclonal antibodies became available, they appeared ideal candidates for use as anti-cancer drugs. However, monoclonal antibodies as currently constituted still have certain inherent limitations. Transfectomas provide an approach to overcoming some of these limitations. Genetically engineered antibodies can be expressed following gene transfection into lymphoid cells. One of the major advantages of expressing genetically engineered antibodies, is that one is not limited to using antibodies as they occur in nature. In particular, non-immunoglobulin sequences can be joined to antibody sequences creating multi-functional chimeric antibodies. Creation of a family of multi-functional chimeric antibodies with a growth factor joined to a combining specificity may be useful in targeting therapy to malignant cells and delivering drugs into specific locales in the human body. Presence of the growth factor may facilitate transcytosis of chimeric antibody across the blood-brain barrier using growth factor receptors. These novel chimeric antibodies constitute a new family of immunotherapeutic molecules for cancer therapy.
抗体因其固有的特异性，似乎是识别和破坏恶性细胞的理想因子。当单克隆抗体可用时，它们似乎是用作抗癌药物的理想候选物。然而，目前构成的单克隆抗体仍然存在某些固有的局限性。转染瘤提供了一种克服其中一些局限性的方法。基因工程抗体可在基因转染到淋巴细胞后表达。表达基因工程抗体的主要优点之一是，人们不限于使用天然存在的抗体。特别是，非免疫球蛋白序列可与抗体序列连接，从而产生多功能嵌合抗体。创建一个将生长因子与结合特异性连接的多功能嵌合抗体家族，可能有助于将靶向治疗应用于恶性细胞，并将药物递送到人体的特定部位。生长因子的存在可能有助于利用生长因子受体使嵌合抗体通过血脑屏障进行转胞吞作用。这些新型嵌合抗体构成了用于癌症治疗的新的免疫治疗分子家族。
